Background Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive lipid storage disorder characterized by a heterogeneous presentation and a broad spectrum of clinical manifestations. Since early diagnosis and replacement therapy with chenodeoxycholic acid can prevent clinical deterioration, our aim was to develop a diagnostic tool to identify and treat CTX patients at an initial stage of the disease. Methods We devised a suspicion index, composed of weighted scores assigned to indicators such as family history characteristics and common systemic and neurological features, on the basis of a pooled analysis of selected international CTX series. The indicators were classified as very strong (score 100), strong (50) or moderate (25). The suspicion index was then applied retrospectively to our CTX population.
Introduction
Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive lipid storage disease due to mutations of the CYP27A1 gene resulting in deficiency of sterol-27-hydroxylase, which plays a key role in the conversion of cholesterol to bile acids (Cali and Russell 1991) . The enzyme defect is responsible for a sharp decrease in chenodeoxycholic acid (CDCA) and a compensatory increase in the activity of cholesterol 7α-hydroxylase, the rate-limiting enzyme in bile acid synthesis: this leads to accumulation of cholestanol and other bile acid precursors in plasma and tissues, as well as increased urinary excretion of bile alcohols (Björkhem and Hansson 2010) .
CTX patients have been reported from all over the world, and the prevalence of the disease is considered to be underestimated (Lorincz et al 2005) . The clinical picture is characterized by a variable association of systemic signs, such as infantile-onset chronic diarrhea, juvenile cataracts, tendon xanthomas and premature osteoporosis, and neurological symptoms including low intelligence, spasticity, ataxia, epilepsy, parkinsonism, and polyneuropathy (Federico and Dotti 1996) . CTX patients also show variable psychiatric manifestations, including personality, affective and psychotic disorders: they can appear either early in the course of the disease or late complicating the other neurologic disturbances (Fraidakis 2013) . Magnetic resonance imaging (MRI) evidence of bilateral signal abnormalities of the cerebellar dentate nuclei is the major neuroradiological hallmark (Barkhof et al 2000; De Stefano et al 2001) . Since elevated concentrations of serum cholestanol are found in all untreated patients (Pilo de la Fuente et al 2011b) , plasma cholestanol assessment is an extremely useful test for CTX diagnosis. Definitive diagnosis is obtained by molecular analysis of the CYP27A1 gene.
Administration of CDCA strongly decreases synthesis of toxic bile acid intermediates, exerting negative feedback on 7α-hydroxylase and limiting the formation of newly synthesized cholesterol by the liver (Batta et al 1985) . Long-term oral administration of CDCA in CTX patients has been reported to stabilize or improve clinical and laboratory parameters without toxic side-effects (Berginer et al 1984; Salen et al 1987; Samenuk and Koffman 2001; Mignarri et al 2011; Ginanneschi et al 2013; Martini et al 2013) . CDCA may arrest disease progression and prevent neurological deterioration, particularly when started in childhood (Van Heijst et al 1998; Federico and Dotti 2003; Berginer et al 2009) , whereas poor response to CDCA treatment may be recorded when treatment is started once neurological impairment is manifest (Pilo de la Fuente et al 2008; Mignarri et al 2012a; RubioAgusti et al 2012; Yahalom et al 2013) .
Replacement therapy with other bile acids such as ursodeoxycholic acid and taurocholic acid has failed to correct biochemical abnormalities (Koopman et al 1985) . Cholic acid is biochemically effective and has sometimes been preferred to CDCA because it is considered safer, especially in children (Pierre et al 2008) , but long term clinical data on its efficacy in CTX are not yet available. Inhibitors of HMG-CoA reductase associated with CDCA have also been tried with contradictory results (Nakamura et al 1991; Salen et al 1994; Verrips et al 1999) . In our experience they do not provide any real longterm benefit. Oral CDCA therefore remains the elective treatment for CTX.
All authors agree on the need for early diagnosis and timely introduction of replacement therapy, since CTX is a chronic disorder leading to progressive deterioration and premature death if not treated. However, as there is considerable variation in disease onset, systemic involvement and neurological impairment, its recognition at an initial stage may be challenging in the clinical setting. This prompted us to develop a simple practical diagnostic algorithm for early identification of CTX patients.
Materials and methods
The study was conducted in three phases. In the first, we performed a pooled analysis of selected CTX series to obtain data to use for building a suspicion index (SI). In the second phase, we developed a diagnostic tool consisting of the SI and an associated flow chart. In the third phase, we applied the SI retrospectively to our population to assess the degree to which diagnosis could be brought forward. The study was approved by the local ethics committee. All patients gave informed consent for data collection.
Phase 1: retrospective evaluation of selected CTX series We carried out a MEDLINE search from 1982 to 2013 using the key word "cerebrotendinous xanthomatosis", and reviewed all the published articles. To include data in the pooled analysis, studies were selected on the basis of the following criteria: 1) CTX diagnosis based on the finding of CYP27A1 gene mutations and/or clinical and biochemical criteria; 2) availability of clinical and laboratory data; 3) sample size≥10 patients. In the case of articles from the same group, we selected the one reporting the greatest number of patients and/or the most complete information. Articles from which it was not possible to extract crude data were excluded.
We also performed a retrospective evaluation of the clinical data of 55 CTX patients (28 females, 27 males) belonging to 39 unrelated families. The median age of our subjects was 36 years (range 1-67). All patients were diagnosed in our Unit for Neurometabolic Disorders in the period 1986 to 2012 and were evaluated clinically by three neurologists experienced in CTX (AF, AM and MTD). The medical records were available for consultation in our archives, enabling us to establish frequency and age of onset of symptoms, age at diagnosis and genotype. In 37 out of 55 patients, serum cholestanol levels at diagnosis were assessed and compared with those of normal controls. When present, instrumental tests such as brain CT and/or MRI scans, electrophysiological studies and bone densitometry were analyzed. Articles by our group reporting part of the patients analyzed herein and fulfilling the criteria for inclusion in the pooled analysis were not considered because of the reappraisal made in the present study.
Phase 2: development of the diagnostic tool To build the SI we itemized family history characteristics as well as systemic and neurological features. We attributed weighted scores to each parameter on the basis of three criteria: frequency, peculiarity and age at manifestation, as pointed out in the review. We assigned the following scores: 100 for very strong indicators, 50 for strong indicators and 25 for moderate indicators. To bring diagnosis forward, we ascribed more strength to childhood-onset indicators and less strength to adult-onset indicators. We also aimed at indicators which are easy to evaluate in clinical practice and do not require expensive tests. After creating the SI, we built a diagnostic flow chart based on its application.
Phase 3: application of the diagnostic tool to our patient population
The diagnostic algorithm obtained in the second phase was applied retrospectively to our 55 patients with a genetic diagnosis of CTX. For each subject we calculated age and SI score at diagnosis, as well as the age at which diagnosis could have been established using the SI. All indicators were detailed. We did not apply the diagnostic tool to the other international CTX series selected for the review, because of the lack of complete information regarding the presence and/or the age at manifestation of each indicator.
Statistical analysis
We tested all data for normal distribution with the Kolmogorov-Smirnov distance method. Cholestanol concentrations were compared with those of normal controls, using Student's t-test. Ages at diagnosis were compared with those obtained applying the diagnostic tool, using one-way analysis of variance (ANOVA). If ANOVA showed a significant difference, Bonferroni's multiple comparison test was performed. Statistical significance was assumed for p<0.01. Table 1 summarizes the results of the review of the selected CTX populations including our cohort and other four international series (Berginer et al 1984; Verrips et al 2000a; Lee et al 2001; Pilo de la Fuente et al 2011a) . We analyzed a total of 170 patients from Europe (Italy, Netherlands, Spain, Belgium, Germany, UK), North America (USA), Africa (Tunisia) and Asia (Israel, China).
Results

Review of selected international CTX series
We documented a substantial diagnostic delay (20-25 years): patients were referred to clinicians during childhood or adolescence (9-19 years), but diagnosis of CTX was made during the fourth decade (34-38 years). At the time of diagnosis, all patients who underwent serum cholestanol assessment (130/130) showed elevated concentrations.
Among systemic manifestations, tendon xanthomas and cataract were the most frequent (69 % and 88 %, respectively): age at presentation was earlier for cataract, which was usually diagnosed in the second decade, while xanthomas were observed later during the third decade. Chronic unexplained diarrhea was present in about half of patients, with onset in childhood and frequent referral to pediatricians. We also observed an increased incidence of prolonged unexplained neonatal cholestatic jaundice. Osteoporosis was frequent in our population, but was usually revealed by bone densitometry in the fourth decade at the time of the diagnosis.
Neurological manifestations covered a broad range of signs and symptoms. Motor disturbances including spastic paraparesis and ataxia were very frequent (77 % and 62 %, respectively), and typically presented at the end of the third decade. We also observed parkinsonism in some cases, with later onset. Notably, more than half the subjects had mild/moderate intellectual disability: early childhood developmental milestones were achieved punctually, but patients showed learning difficulties with poor school performance, sustained infantile behavior and lack of ageappropriate self-care skills. Psychiatric disturbances, including depression, bipolar disorder, anxiety, panic disorder and psychosis, were reported in about half the patients, typically manifesting in the third decade. Epilepsy was reported in one third of cases, with variable age of onset. Axonal or demyelinating polyneuropathy was documented by neurophysiological study in 66 % (71/108) of cases; however, neuropathy was often subclinical and was usually diagnosed in the third/fourth decade. Brain MRI revealed dentate nuclei signal abnormalities in 75 % (62/83) of patients, but this typical neuroradiological finding was usually documented in the fourth decade at the time of diagnosis.
Family history showed consanguinity in one third of families.
CTX suspicion index and diagnostic flow chart Table 2 shows the proposed suspicion index (SI) for use by clinicians to calculate the total CTX prediction score.
We divided the diagnostic indicators into three categories:
I) Family history: sibling with CTX; consanguineous parents. II) Systemic: tendon xanthomas; juvenile cataract; childhoodonset chronic diarrhea; prolonged unexplained neonatal jaundice or cholestasis; early osteoporosis. III) Neurological: cerebellar ataxia; spastic paraparesis; MRI evidence of dentate nuclei signal alterations; intellectual disability; psychiatric disturbances; epilepsy; parkinsonism; polyneuropathy.
These indicators were grouped into very strong, strong, and moderate:
A) Very strong indicators: A1) sibling with CTX; A2) tendon xanthomas. B) Strong indicators: B1) consanguineous parents; B2) juvenile cataract; B3) childhood-onset chronic diarrhea; B4) prolonged unexplained neonatal jaundice or cholestasis; B5) ataxia (a) and/or spastic paraparesis (b); B6) MRI evidence of dentate nuclei signal alterations; B7) intellectual disability (a) and/or psychiatric disturbances (b). C) Moderate indicators: C1) early osteoporosis; C2) epilepsy; C3) parkinsonism; C4) polyneuropathy.
The following scores were assigned to weigh the variables: 100 for each very strong indicator; 50 for each strong indicator; 25 for each moderate indicator. Although indicators B5 and B7 included two different signs (a and b), one or both Age at onset and age at diagnosis are expressed as mean ± standard deviation Signs and symptoms are expressed as percentage; when reported, age at manifestation/diagnosis (mean ± standard deviation) of the sign or symptom is also indicated BD bone densitometry, EMG electromyography, F females, M males, MRI magnetic resonance imaging signs in the same patient (a and/or b) scored 50 alike. After creating the SI, we built a diagnostic flow chart based on its application (Fig. 1) . A total score≥100 warranted assessment of serum cholestanol concentrations, which had to be measured in the absence of treatment with bile acids and statins as well as corticosteroids, since steroids can lower plasma cholestanol by inducing residual CYP27A1 activity or cholestanol elimination (Siman-Tov et al 2006) . Evidence of increased plasma cholestanol suggested CYP27A1 gene sequencing, while normal serum cholestanol levels indicated a different diagnosis. However, two other conditions were established to be sufficient to sequence CYP27A1, irrespective of cholestanol assessment: i) a total score≥200 with at least one very strong or four strong indicators; ii) a sibling with genetically confirmed CTX. According to our flow chart, CTX can only be diagnosed definitively on the basis of CYP27A1 molecular analysis.
Application of the diagnostic tool to our CTX patient population
We applied the SI to our patient population consisting of 55 patients. For each subject we determined: I) age, serum cholestanol (available in 37/55), SI score and indicators at the time of diagnosis; II) age and indicators at the time when SI score reached 100; III) age and indicators at the time when SI score reached 200 (with presence of at least one very strong or four strong indicators). Figure 2 shows age at diagnosis (minimum, 25th percentile, median, 75th percentile, maximum) of each clinical indicator. At diagnosis, median age was 36 years (mean 35.5±11.8 standard deviation [SD] ) and the median SI score was 300 (mean 298.2±66.6 SD). Serum cholestanol concentrations were elevated in 35/35 patients: mean 2.94±1.21 mg/dl against 0.22 ± 0.08 mg/dl in 17 age-matched controls (p<0.0001).
For each patient, we calculated when SI score reached 100 and 200: mean age (±SD) at SI≥100 was 10.6±9.8 years, and mean age at SI≥200 was 24.1±11.4 years. When we compared the age at actual diagnosis with the ages at SI≥100 and SI≥200, we found statistically significant differences between the three groups (p<0.01). The mean difference between age at actual diagnosis and age at SI≥100 and SI≥200 was 25.1± 11.8 years and 12.0±9.5 years, respectively. Figure 3 shows age at diagnosis, age at SI≥100 and age at SI≥200 (all expressed as minimum, 25th percentile, median, 75th percentile, and maximum).
Indicators at diagnosis, SI≥100 and SI≥200 are detailed in Fig. 4 . Notably, disabling neurological indicators such as ataxia, spastic paraparesis and psychiatric disturbances were very frequent at diagnosis and almost absent at SI≥100. On the other hand, intellectual impairment and epilepsy were found at an earlier stage of the disease. Among systemic indicators, tendon xanthomas and cataract were present in most patients at diagnosis, but xanthomas were found in few subjects at SI≥100 while cataract manifested earlier. Chronic diarrhea and neonatal jaundice were not as frequent as the above systemic indicators, but their early appearance made them very important for timely diagnosis. Other indicators such as MRI evidence of dentate nuclei signal alterations, osteoporosis, parkinsonism and polyneuropathy were never found at SI≥100.
Discussion
In the present study we reviewed the largest available series of CTX cases analyzed together, and we developed a suspicion index (SI) to achieve early diagnosis of this treatable metabolic disorder.
We assigned a higher score to tendon xanthomas than to juvenile cataract, despite the higher frequency of the latter. Indeed, tendon xanthomas point strongly to CTX, although they may also be observed in sitosterolemia, which is very rare and does not share other phenotypical manifestations with CTX, and occasionally in familial hypercholesterolemia. On the other hand, juvenile cataract may also occur in a number of disorders causing neurological manifestations and requiring differential diagnosis with CTX, such as galactosemia (which also shares diarrhea and jaundice with CTX), MarinescoSjögren syndrome and myotonic dystrophy type 1. Our review highlighted the frequency and childhood manifestation of chronic diarrhea, confirming the findings of previous studies (Cruysberg et al 1991; Verrips et al 2000b; Cruysberg 2009; Berginer et al 2009) and further emphasising the importance of this symptom for early diagnosis. We also considered prolonged unexplained neonatal jaundice or cholestasis as a strong diagnostic indicator. Nevertheless, several single case reports have described neonatal cholestatic jaundice as a possible early manifestation of CTX (Clayton et al 2002; von Bahr et al 2005; Pierre et al 2008) . Of note, unexplained neonatal cholestatic jaundice can also be observed in Niemann-Pick disease type C, another autosomal recessive lipid storage disorder. Early osteoporosis is a common systemic manifestation of CTX (Berginer et al 1993; Martini et al 2013) , but since it is often subclinical and only detectable by bone densitometry, its importance as diagnostic indicator is limited.
We considered spastic paraparesis, cerebellar ataxia, intellectual disability and psychiatric disturbances to be strong Fig. 3 Box plot representing age at diagnosis, age at SI≥100 and age at SI≥200 (all expressed as minimum, 25th percentile, median, 75th percentile, and maximum) in our 55 CTX patients. A statistically significant difference was observed between the three groups (p<0.01). Legend: diag. diagnosis Intellectual disability, usually presenting in the school age, is particularly important to consider for early diagnosis. Epilepsy was classified as a moderate CTX diagnostic indicator: this early-onset symptom is not very frequent and also occurs in a multitude of neurometabolic disorders. Parkinsonism was found in some patients of our population but was not reported in the other four series: we included it in the SI as a moderate indicator because of increasing evidence that it could be an underestimated neurological manifestation of CTX (Su et al 2010; Mignarri et al 2012b; Rubio-Agusti et al 2012) . MRI evidence of dentate nuclei signal alterations was considered a strong diagnostic indicator because in spite of its elevated frequency and peculiarity, it appears relatively late. Finally, we included polyneuropathy as a moderate indicator: neurophysiologically confirmed neuropathy is very frequent in CTX, but signs or symptoms are often absent or difficult to appreciate because central nervous system involvement usually dominates the clinical picture (Pilo et al 2011; Ginanneschi et al 2013) .
We proposed a diagnostic flow chart based on our SI, and established a total SI score≥100 as sufficient to assess serum cholestanol. We assigned an important diagnostic role to serum cholestanol assessment for three main reasons: first, our review confirmed that all untreated CTX patients show very elevated plasma cholestanol levels; second, we are not aware of high cholestanol concentrations in normal controls and patients with other diseases; third, plasma cholestanol assessment is easy to perform. Although serum cholestanol analysis in patients with SI≥100 could involve a considerable overall cost, early diagnosis and treatment may prevent neurological disability and high related social and health costs in the long term.
The diagnostic gold standard is molecular analysis of the CYP27A1 gene. Our flow chart recommends genetic analysis for patients with a total SI score≥200 and at least one very strong indicator or four strong indicators, and for all siblings of CTX patients, even those with normal cholestanol values. This ensures that diagnosis is not missed in cases with a clinical picture highly suggestive of CTX or an elevated statistical probability of being affected.
Notably, our SI is very easy to apply in the clinical setting: indeed, most of the indicators can be determined from medical history and clinical examination.
Although our diagnostic algorithm was proved to be useful for early diagnosis, a pediatric screening program may be also needed. Assessment of serum cholestanol in children with neonatal cholestatic jaundice, cataract or unexplained chronic diarrhea may allow very early diagnosis and treatment of CTX, but could involve a great number of patients as well as considerable costs. This aspect deserves further epidemiological studies with a pediatric perspective. Fig. 4 Frequency of the indicators at diagnosis, at SI≥200 and at SI≥100 in our patient population A limitation of this study was due to the fact that we could not test our diagnostic tool in false positive cases, as the number of subjects who underwent testing of cholestanol levels and/or CYP27A1 analysis in our laboratory in the last 20 years was limited and therefore not statistically significant. However, this point may be less important because the aim of the present study was to enable earlier diagnosis rather than to improve differential diagnosis.
Early diagnosis and timely introduction of replacement therapy are unanimously considered to be crucial in CTX patients in order to prevent neurological disability. However, our review pointed out a marked delay between symptoms onset and diagnosis. A recent cross-sectional observational study evaluating the long-term neurological outcome of CTX patients treated with CDCA revealed that subjects who started therapy after the age of 25 years had worse outcome and were significantly more limited in ambulation and cognition (Yahalom et al 2013) . Our results show that the present suspicion index could allow early diagnosis of CTX, so that treatment can be started before disability occurs. We therefore propose its use in clinical practice and hope for validation and discussion in future studies.
